Back to news
Articles
BioCopy Advances Lead Lung Cancer Program into Preclinical Development
Basel, 19 June 2026 — BioCopy AG has announced a major scientific milestone with the completion of candidate selection for its MAGE-A4 lung cancer program, marking the transition of its lead asset into preclinical development.
The selected molecule is a TCR-mimetic bispecific T-cell engager designed to target intracellular cancer antigens, a segment representing approximately 73% of all cancer targets but which remains largely inaccessible to conventional antibody therapies. The program will now advance into IND-enabling safety and efficacy studies, with the company targeting completion of its IND package by Q3 2027.
This milestone represents an important validation of BioCopy’s proprietary ValidaTe discovery platform, which integrates SCORE, EpiPredict and EpiTox technologies to identify and optimize highly selective immuno-oncology candidates. According to the company, the selected MAGE-A4 candidate has demonstrated superior performance in laboratory benchmarks compared to competing clinical-stage molecules.
In parallel, BioCopy continues to advance additional discovery programs targeting bladder, liver and ovarian cancers.
Alongside this scientific progress, BioCopy has also provided an update on its ongoing Series A financing round. Following the previously completed first CHF 9 million tranche, the Board of Directors has now accepted subscriptions for an additional CHF 9 million, bringing total committed capital to CHF 18 million out of the CHF 24 million target. The final CHF 6 million tranche is now open for subscription.
The financing will support the company’s expanding preclinical immuno-oncology pipeline and provide additional resources for the execution of its “Road to IND” strategy.
About BioCopy SA
BioCopy SA is a Swiss-German biopharmaceutical company headquartered in Basel, with an R&D facility in Emmendingen (Germany). The company combines proprietary ultra-high-throughput screening technologies, artificial intelligence and wet-lab experimental feedback to develop next-generation biotherapeutics in immuno-oncology.
About Haute Capital Partners SA
Haute Capital Partners (BX Swiss: HAUTE) is Switzerland's listed private equity holding. Access high-growth Swiss companies through a single tradeable share, denominated in CHF. The company's registered shares are listed on the BX Swiss: Ticker: HAUTE | ISIN: CH1115678950 | Valor: 111567895 | www.haute.com
Investor Inquiries
Haute Capital Partners SA
+41 32 321 35 35 | ir@haute.com
Media & General inquiries
Haute Capital Partners SA
+41 32 321 35 35 | info@haute.com
DISCLAIMER
This publication constitutes neither an offer to sell nor a solicitation to buy securities of the Company and it does not constitute a prospectus or a similar communication within the meaning of article 652a, 752 and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the BX Swiss. The listing is being made solely by means of and based on the published securities prospectus (including any amendments thereto, if any). An investment decision regarding the securities of the Company should only be made based on the securities prospectus. The prospectus is available free of charge in Switzerland for 12 months following the first day of trading at HAUTE CAPITAL PARTNERS SA, Plänkestrasse 32, 2502 Biel/Bienne, Switzerland. This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. This communication does not constitute an "offer of securities to the public" within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The issuer of the securities has not registered, and does not intend to register, any portion of the securities in the United States, and does not intend to conduct a public offering of securities in the United States.